MAPT and Alzheimer disease: In that study, it was found that individuals with normal levels of both Aβ and tau in cerebrospinal fluid (CSF) performed better on cognitive tests, but excluding these individuals with preclinical AD from normative datasets did not increase predictive accuracy of clinical decline in cognitively normal individuals (Hassenstab et al., 2016).